Trade Summary

Yesterday, Mortimer Ian, serving as Pres, CEO at Xenon Pharmaceuticals Inc. (XENE), sold 40,000 shares at $44.43 per share, for a total transaction value of $1,777,093.00. Following this transaction, Mortimer Ian now holds 20,300 shares of XENE.

This sale represents a 66.00% decrease in Mortimer Ian's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, January 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, January 2, 2026, meaning the disclosure happened on the same day as the trade.

Xenon Pharmaceuticals Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.